Advertisement

Tumor Biology

, Volume 36, Issue 2, pp 799–805 | Cite as

Decreased expression of EFS is correlated with the advanced prostate cancer

  • Selda Sertkaya
  • Syed Muhammad Hamid
  • Nihat Dilsiz
  • Lokman Varisli
Research Article

Abstract

Prostate cancer is the most frequently diagnosed malignant neoplasm in men in the developed countries. Although the progression of prostate cancer and the processes of invasion and metastasis by tumor cells are comparatively well understood, the genes involved in these processes are not fully determined. Therefore, a common area of research interest is the identification of novel molecules that are involved in these processes. In the present study, we have used in silico and experimental approaches to compare the expression of embryonal Fyn-associated substrate (EFS) between normal prostate and prostate cancer. We showed that EFS expression is remarkably downregulated in prostate cancer cells, compared to normal prostate cells. We also found that decreased expression of EFS in prostate cancer cells is due to DNA methylation. In addition, we showed that high EFS expression is important to suppress a malignant behavior of prostate cancer cells. Therefore, we suggest that EFS should be considered as a novel tumor suppressor gene in prostate cancer.

Keywords

EFS Prostate cancer DNA methylation 

Abbreviations

PCa

Prostate cancer

EFS

Embryonal Fyn-associated substrate

CAS

Crk-associated substrate

BCAR1

Breast cancer resistance 1

NEDD9

Neural precursor cell expressed, developmentally downregulated 9

HEPL

HEF1-EFS-P130 Cas-like

FBS

Fetal bovine serum

5-Aza

5′-Aza-2′-deoxycytidine

TSA

Trichostatin A

TBS-T

Tris-buffered saline containing 0.1 % Tween 20

PVDF

Polyvinyledine fluoride

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

Notes

Acknowledgments

We would like to thank all the members of Harran University Central Laboratory (HUMEL) for their help and assistance. We would also like to thank Prof. Dr. Kemal S. Korkmaz from Ege University, Department of Bioengineering, İzmir, Turkey, for providing PC-3, DU145, and LNCaP cell lines and Assoc. Prof. Dr. Omer Faruk Bayraktar from Yeditepe University, Medical Faculty, Department of Medical Biology, Istanbul, Turkey, for providing PNT1a cell line. This study was supported by grants 113S433 and 113S290 from the Scientific and Technological Research Council of Turkey (TUBITAK) and 13044 from Harran University Scientific Research Project Unit (HUBAK) to L.V.

Conflicts of interest

None

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001;61:5974–8.PubMedGoogle Scholar
  3. 3.
    Chen AH, Tsau YW, Lin CH. Novel methods to identify biologically relevant genes for leukemia and prostate cancer from gene expression profiles. BMC Genomics. 2010;11:274.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002;1:203–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22:2790–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, Klacansky I, et al. In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A. 2004;101:615–20.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007;7:64.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Varisli L. Identification of new genes downregulated in prostate cancer and investigation of their effects on prognosis. Genet Test Mol Biomark. 2013;17:562–6.CrossRefGoogle Scholar
  9. 9.
    Brinkman A, van der Flier S, Kok EM, Dorssers LC. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst. 2000;92:112–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in saccharomyces cerevisiae. Mol Cell Biol. 1996;16:3327–37.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Singh MK, Dadke D, Nicolas E, Serebriiskii IG, Apostolou S, Canutescu A, et al. A novel Cas family member, HEPL, regulates FAK and cell spreading. Mol Biol Cell. 2008;19:1627–36.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ishino M, Ohba T, Sasaki H, Sasaki T. Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn. Oncogene. 1995;11:2331–8.PubMedGoogle Scholar
  13. 13.
    Cabodi S, del Pilar C-LM, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer. 2010;10:858–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Alexandropoulos K, Baltimore D. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin. Genes Dev. 1996;10:1341–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010;67:1025–48.CrossRefPubMedGoogle Scholar
  16. 16.
    Neumann LC, Weinhausel A, Thomas S, Horsthemke B, Lohmann DR, Zeschnigk M. EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation. BMC Cancer. 2011;11:380.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. Oncomine: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Varisli L. Meta-analysis of the cell cycle related C12orf48. Biocell. 2013;37:11–6.PubMedGoogle Scholar
  19. 19.
    Varisli L. Meta-analysis of the expression of the mitosis-related gene Fam83D. Oncol Lett. 2012;4:1335–40.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Varisli L, Gonen-Korkmaz C, Syed HM, Bogurcu N, Debelec-Butuner B, Erbaykent-Tepedelen B, et al. Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences ar mediated transactivation in prostate cells. Mol Cell Endocrinol. 2012;350:107–17.CrossRefPubMedGoogle Scholar
  21. 21.
    Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, Baay M, et al. Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software. Phys Med Biol. 2010;55:N167–78.CrossRefPubMedGoogle Scholar
  22. 22.
    Pulukuri SM, Rao JS. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene. 2006;25:4559–72.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002;62:4499–506.PubMedGoogle Scholar
  24. 24.
    Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39:41–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res. 2009;15:5794–802.CrossRefPubMedGoogle Scholar
  26. 26.
    Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, et al. Gene expression analysis of prostate cancers. Mol Carcinog. 2002;33:25–35.CrossRefPubMedGoogle Scholar
  27. 27.
    Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One. 2008;3:e2318.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Karayi MK, Markham AF. Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis. 2004;7:6–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Donlin LT, Danzl NM, Wanjalla C, Alexandropoulos K. Deficiency in expression of the signaling protein Sin/Efs leads to T-lymphocyte activation and mucosal inflammation. Mol Cell Biol. 2005;25:11035–46.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Alexandropoulos K, Donlin LT, Xing L, Regelmann AG. Sin: good or bad? A T lymphocyte perspective. Immunol Rev. 2003;192:181–95.CrossRefPubMedGoogle Scholar
  33. 33.
    Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer J Int du Cancer. 2007;121:2373–80.CrossRefGoogle Scholar
  34. 34.
    Tikhmyanova N, Golemis EA. NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One. 2011;6:e22102.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Selda Sertkaya
    • 1
  • Syed Muhammad Hamid
    • 2
  • Nihat Dilsiz
    • 3
  • Lokman Varisli
    • 1
  1. 1.Arts and Science Faculty, Department of Biology, Cancer Biology LaboratoryHarran UniversitySanliurfaTurkey
  2. 2.Faculty of Science, Department of Molecular Biology and GeneticsIzmir Institute of TechnologyIzmirTurkey
  3. 3.Arts and Science Faculty, Department of Molecular Biology and GeneticsHarran UniversitySanliurfaTurkey

Personalised recommendations